Monday, August 2, 2021
HomeNewsMedidata Acorn AI Synthetic Control Arm Named “Best AI-Based Solution For Healthcare”...

Medidata Acorn AI Synthetic Control Arm Named “Best AI-Based Solution For Healthcare” By 2021 AI Breakthrough Awards

Medidata recently announced that it had been named the best artificial intelligence-based solution for healthcare by AI Breakthrough Awards in 2021. 

The AI Breakthrough Awards honors excellence and recognizes innovation in a range of artificial intelligence and machine learning related categories, including artificial intelligence platforms, deep learning, health-tech, natural language processing, smart robotics, business intelligence, industry-specific artificial intelligence applications, and many more.

In this crowded artificial intelligence market during the COVID-19 pandemic situation, Medidata has revolutionized the world of clinical trials through its unique approach to external controls with its Synthetic Control Arm. It is a type of external control, which is generated from patient data during clinical trials. 

Read More: Xactly Forecasting Wins 2021 Artificial Intelligence Breakthrough Award

The main reason for the success of this solution is the vast data pool of over seven million patients, which has helped to improvise Medidata’s synthetic control arm. 

Arnaud Chatterjee, Senior Vice President of Medidata Acron AI products, said, “Because patients who are seeking treatment through clinical trials have often already considered standard of care treatments and found them unpleasing, many patients view an investigational drug as an opportunity for something better, especially with rare and life-threatening diseases.” 

He also mentioned that the possibility of being placed in a control group could discourage patients from participating in clinical trials. However, at Acron AI, patients are allowed more comprehensive access to potentially life-saving therapies by utilizing data and analytics capabilities.  

The United States’s Food and Drug Administration (FDA) has recently given permission to Medidata for conducting a registration-based third phase of clinical trials of their groundbreaking artificial intelligence-powered technology.  

Medidata is a Now York-based health tech company founded in 1999. It is a subsidiary of Dassault Systemes, which uses its 3D Experience platform to transform the healthcare industry.

Subscribe to our newsletter

Subscribe and never miss out on such trending AI-related articles.

We will never sell your data

Join our Telegram and WhatsApp group to be a part of an engaging community.

Dipayan Mitra
Dipayan is a news savvy writer, who does not leave a single page of news paper unturned. He is also a professional vocalist who enjoys ghazals. Building a dog shelter is his forever dream.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -
- Advertisment -

Most Popular